Two additional CB2-selective agonists, JWH-015 and JWH-133, showed comparable efficacy to THC in modulating IFNα and TNFα responses by pDC, demonstrating the potential for CB2-targeted therapeutics for the treatment of inflammatory conditions involving aberrant pDC activity, such as SLE [185]. The gene discussed is CNR2; the disease is systemic lupus erythematosus.